MX2021013849A - 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1, 2,4-triazol-3-il]piridina para usar en la prevencion y/o el tratamiento del dolor en un animal. - Google Patents
4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1, 2,4-triazol-3-il]piridina para usar en la prevencion y/o el tratamiento del dolor en un animal.Info
- Publication number
- MX2021013849A MX2021013849A MX2021013849A MX2021013849A MX2021013849A MX 2021013849 A MX2021013849 A MX 2021013849A MX 2021013849 A MX2021013849 A MX 2021013849A MX 2021013849 A MX2021013849 A MX 2021013849A MX 2021013849 A MX2021013849 A MX 2021013849A
- Authority
- MX
- Mexico
- Prior art keywords
- pain
- prevention
- treatment
- rac
- triazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a 4-[5-[(rac)-1-[5-(3-clorofenil) -3-isoxazolil]etoxi]-4-metil-4H-1,2,4-triazol-3-il]piridina (TT00), o una sal farmacéuticamente aceptable del mismo, diastereómero, enantiómero, isótopo, profármaco o metabolito o mezcla de los mismos, o una composición farmacéutica que comprende dicho TT00, para usar en la prevención y/o el tratamiento del dolor, tal como el dolor crónico y/o periférico y/o el dolor relacionado con la artritis, tal como la osteoartritis, o para usar en la prevención y/o el tratamiento de dicho dolor combinado con b) ERGE o c) ansiedad en animales, tales como perros, gatos o caballos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1950579 | 2019-05-15 | ||
| PCT/EP2019/082264 WO2020228973A1 (en) | 2019-05-15 | 2019-11-22 | 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of pain in an animal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013849A true MX2021013849A (es) | 2022-01-07 |
Family
ID=68733027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013849A MX2021013849A (es) | 2019-05-15 | 2019-11-22 | 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1, 2,4-triazol-3-il]piridina para usar en la prevencion y/o el tratamiento del dolor en un animal. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12427140B2 (es) |
| EP (1) | EP3927343A1 (es) |
| JP (1) | JP7444901B2 (es) |
| KR (1) | KR20220008828A (es) |
| CN (1) | CN113811297B (es) |
| AU (1) | AU2019445424B2 (es) |
| BR (1) | BR112021019911A2 (es) |
| CA (1) | CA3136142A1 (es) |
| IL (1) | IL287894A (es) |
| MX (1) | MX2021013849A (es) |
| WO (1) | WO2020228973A1 (es) |
| ZA (1) | ZA202107823B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220387410A1 (en) * | 2019-11-05 | 2022-12-08 | Claes Thulin | 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal |
| WO2024088712A1 (en) * | 2022-10-28 | 2024-05-02 | Orphelion Ab | Mglur5 receptor antagonists for use in prevention and/or treatment of bone marrow lesions (bml) and/or osteoporosis, cartilage loss, osteosclerosis, osteitis in a mammal |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105533B2 (en) * | 2002-09-13 | 2006-09-12 | Merck & Co., Inc. | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators |
| US7393959B2 (en) | 2003-04-04 | 2008-07-01 | Merck & Co. Inc. | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| UY29796A1 (es) | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| TW200823196A (en) * | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New use |
-
2019
- 2019-11-22 MX MX2021013849A patent/MX2021013849A/es unknown
- 2019-11-22 US US17/604,750 patent/US12427140B2/en active Active
- 2019-11-22 JP JP2021565049A patent/JP7444901B2/ja active Active
- 2019-11-22 CA CA3136142A patent/CA3136142A1/en active Pending
- 2019-11-22 AU AU2019445424A patent/AU2019445424B2/en active Active
- 2019-11-22 KR KR1020217037412A patent/KR20220008828A/ko not_active Ceased
- 2019-11-22 CN CN201980096334.4A patent/CN113811297B/zh active Active
- 2019-11-22 EP EP19812939.7A patent/EP3927343A1/en active Pending
- 2019-11-22 BR BR112021019911A patent/BR112021019911A2/pt not_active Application Discontinuation
- 2019-11-22 WO PCT/EP2019/082264 patent/WO2020228973A1/en not_active Ceased
-
2021
- 2021-10-14 ZA ZA2021/07823A patent/ZA202107823B/en unknown
- 2021-11-07 IL IL287894A patent/IL287894A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220040165A1 (en) | 2022-02-10 |
| IL287894A (en) | 2022-01-01 |
| JP7444901B2 (ja) | 2024-03-06 |
| AU2019445424A1 (en) | 2021-10-14 |
| AU2019445424B2 (en) | 2025-02-27 |
| CN113811297B (zh) | 2024-03-26 |
| JP2022532869A (ja) | 2022-07-20 |
| KR20220008828A (ko) | 2022-01-21 |
| CA3136142A1 (en) | 2020-11-19 |
| BR112021019911A2 (pt) | 2021-12-07 |
| WO2020228973A1 (en) | 2020-11-19 |
| ZA202107823B (en) | 2023-10-25 |
| US12427140B2 (en) | 2025-09-30 |
| CN113811297A (zh) | 2021-12-17 |
| EP3927343A1 (en) | 2021-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2682303T3 (es) | Derivados de isoxazolina como agentes antiparasitarios | |
| WO2013009827A1 (en) | Methods of treatment | |
| MX2022007105A (es) | Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico. | |
| NZ592258A (en) | Pesticidal (hetero) arylpyrrolidines | |
| FI3721882T3 (fi) | Aineenvaihduntahäiriöiden hoito hevoseläimissä | |
| HRP20160355T1 (hr) | Kristalni oblici 4-[5-[3-kloro-5-(trifluorometil)fenil]-4,5-dihidro-5-(trifluorometil)-3-izoksazolil]-n-[2-okso-2-[(2,2,2-trifluoroetil)amino]etil]-1-naftalenkarboksamida | |
| RU2481330C2 (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
| SI2957284T1 (en) | Procedure for controlling animal pests | |
| JP2016512825A5 (es) | ||
| JP2017160233A5 (es) | ||
| JP2020516671A5 (es) | ||
| WO2013009830A1 (en) | Methods of treatment | |
| JP2014511869A5 (es) | ||
| AR106735A1 (es) | Composiciones y métodos insecticidas | |
| WO2013009810A1 (en) | Methods of treatment | |
| BR112019006228A2 (pt) | tratamento de câncer de próstata | |
| HRP20160421T1 (hr) | Derivat azola | |
| RU2019121667A (ru) | Аминопиразолы в качестве селективных ингибиторов янус-киназы | |
| MX2021013849A (es) | 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1, 2,4-triazol-3-il]piridina para usar en la prevencion y/o el tratamiento del dolor en un animal. | |
| AU2015371175B2 (en) | Use of isoxazoline compounds for treating demodicosis | |
| RU2017134379A (ru) | Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 | |
| JP2008516922A5 (es) | ||
| JP2009532438A5 (es) | ||
| HK1255438A1 (zh) | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 | |
| CL2020003162A1 (es) | Método de administración de una cantidad terapéuticamente efectiva de 5-[[4-[2-[5-(1- hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona |